{"filing":{"accession_number":"0001437749-26-031419","cik":"0001659617","ticker":"MBRX","company_name":"Moleculin Biotech, Inc.","form":"8-K","filing_date":"2026-09-29","report_date":"2026-09-29","primary_document":"mbrx20260928_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926031419/mbrx20260928_8k.htm"},"events":[{"id":35636,"run_id":32833,"accession_number":"0001437749-26-031419","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Moleculin announced completion of enrollment in Part A of its pivotal Phase 2/3 MIRACLE trial for Annamycin in R/R AML, with 89 subjects enrolled and a planned Q1 2027 data readout. This is a material clinical development milestone for a Phase 3 stage biopharmaceutical company whose lead program depends on successful trial execution. While not fitting the specific categories of earnings, M\u0026A, impairment, or litigation, this represents a significant operational and strategic milestone in the company's drug development pathway that would affect a reasonable investor's assessment of near-term catalysts and program progress.","company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","filing_date":"2026-09-29","form":"8-K","submitted_at":null,"items":[{"id":39768,"accession_number":"0001437749-26-031419","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Moleculin announced completion of enrollment in Part A of its pivotal Phase 2/3 MIRACLE trial for Annamycin in R/R AML, with 89 subjects enrolled and a planned Q1 2027 data readout. This is a material clinical development milestone for a Phase 3 stage biopharmaceutical company whose lead program depends on successful trial execution. While not fitting the specific categories of earnings, M\u0026A, impairment, or litigation, this represents a significant operational and strategic milestone in the company's drug development pathway that would affect a reasonable investor's assessment of near-term catalysts and program progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T12:47:11.444642+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39768,"accession_number":"0001437749-26-031419","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Moleculin announced completion of enrollment in Part A of its pivotal Phase 2/3 MIRACLE trial for Annamycin in R/R AML, with 89 subjects enrolled and a planned Q1 2027 data readout. This is a material clinical development milestone for a Phase 3 stage biopharmaceutical company whose lead program depends on successful trial execution. While not fitting the specific categories of earnings, M\u0026A, impairment, or litigation, this represents a significant operational and strategic milestone in the company's drug development pathway that would affect a reasonable investor's assessment of near-term catalysts and program progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T12:47:11.444642+00:00","company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","filing_date":"2026-09-29"}]}